Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/principles-of-pharmacogenetics-and-pharmacogenomics/altman/descriptif_2553502
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=2553502

Principles of Pharmacogenetics and Pharmacogenomics

Langue : Anglais

Coordonnateurs : Altman Russ B., Flockhart David , Goldstein David B.

Couverture de l’ouvrage Principles of Pharmacogenetics and Pharmacogenomics
This textbook presents the latest information on pharmacogenetics and pharmacogenomics for students, professionals and researchers.
The study of pharmacogenetics and pharmacogenomics focuses on how our genes and complex gene systems influence our response to drugs. Recent progress in clinical therapeutics has led to the discovery of new biomarkers that make it technically easier to identify groups of patients which are more or less likely to respond to individual therapies. The aim is to improve personalised medicine - not simply to prescribe the right medicine, but to deliver the right drug at the right dose at the right time. This textbook brings together leading experts to discuss the latest information on how human genetics impacts drug response phenotypes. It presents not only the basic principles of pharmacogenetics, but also clinically valuable examples that cover a broad range of specialties and therapeutic areas. This textbook is an invaluable introduction to pharmacogenetics and pharmacogenomics for health care professionals, medical students, pharmacy students, graduate students and researchers in the biosciences.
Introduction to population diversity and genetic testing: basic concepts Russ Altman, David Flockhart and David Goldstein; Part I. Critical Concepts: 1. Introduction to population diversity and genetic testing James K. Burmester, Ingrid Glurich, Kimberly Pillsbury and Michael D. Caldwell; 2. Genotyping technologies Sharon Marsh and Cristi R. King; 3. Pharmacokinetics: absorption, distribution, metabolism, excretion Terry Blaschke; 4. Overview: adverse drug reactions Matthew Nelson; 5. PharmGKB, a centralized resource for pharmacogenomic knowledge and discovery Li Gong and Teri E. Klein; 6. DrugBank David S. Wishart; 7. Ethical considerations for pharmacogenomics: privacy and confidentiality Sandra Lee; 8. Informed consent in pharmacogenomic research and treatment Mark Rothstein; 9. Legal trends driving the clinical translation of pharmacogenomics Barbara Evans; Part II. Therapeutic Areas: 10. Pharmacogenetics of oncologic drugs Uchenna Njaju and Eileen Dolan; 11. Pharmacogenetics of cardiovascular drugs Michael Stein and Danny Kurnik; 12. Pharmacogenomics of statin-induced muscle toxicity Ronald M. Krauss, Russell A. Wilke, Melissa Antonik and Elenita Kanin; 13. Pharmacogenomics of the drug-induced long QT syndrome Dan M. Roden, Prince J. Kannankeril, Stefan Kaab and Dawood Darbar; 14. Pharmacogenetics of diabetes drugs O. H. Klungel and Mark C. H. DeGroot; 15. Pharmacogenetics of respiratory drugs Kelan Tantisira and Scott Weiss; 16. Pharmacogenomics for acid-related gastrointestinal drugs Takahisa Furuta; 17. Pharmacogenetics of rheumatoid arthritis drugs Robert M. Plenge, Yvonne C. Lee, Souomya Raychaudhuri and Daniel H. Solomon; 18. Pharmacogenomics of obstetric drugs David Haas and Jamie Renbarger; 19. Pharmacogenomics of psychiatric drugs David Mrazek; 20. Pharmacogenomics of pain and anesthesia drugs Evan Kharasch and Konrad Meissner; 21. Pharmacogenetics of HIV and antiretroviral drugs Amalio Telenti; 22. Pharmacogenomics in pediatrics Jennifer A. Lowry and J. Steven Leeder; 23. Pharmacogenomics in fetal and neonatal medicine Yair Blumenfeld.
Russ Altman is Chairman of the Bioengineering Department and Professor of Bioengineering, Genetics, and Medicine at Stanford University. His primary research interests are in the application of computing technology to basic molecular biological problems of relevance to medicine.
David Flockhart is the Harry and Edith Gladstein Chair in Cancer Genomics and Professor of Medicine, Medical Genetics and Pharmacology at the Indiana University School of Medicine in Indianapolis. He is also the Director of the Division of Clinical Pharmacology. His research is focused on clinically relevant applications of pharmacogenetics and drug interactions.
David Goldstein is the Richard and Pat Johnson Distinguished University Professor and Director of the Center for Human Genome Variation at Duke University. He is also Professor of Molecular Genetics and Microbiology at Duke. His principal interests include human genetic diversity, the genetics of disease and pharmacogenetics.

Date de parution :

Ouvrage de 282 p.

18.3x26.1 cm

Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).

Prix indicatif 111,58 €

Ajouter au panier

Thème de Principles of Pharmacogenetics and Pharmacogenomics :